{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:25:37Z","timestamp":1785684337671,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.prp.2023.154915","type":"journal-article","created":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T00:29:35Z","timestamp":1698539375000},"page":"154915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["PRAME expression in 137 primary cutaneous melanomas and comparison with 38 related metastases"],"prefix":"10.1016","volume":"251","author":[{"given":"Giuseppe","family":"Lo Bello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo Maria","family":"Pini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Giagnacovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2023.154915_bib1","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","author":"Lezcano","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/PAS.0000000000001492","article-title":"Comparison of immunohistochemistry for PRAME with cytogenetic test results in the evaluation of challenging melanocytic tumors","author":"Lezcano","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/PAS.0000000000001393","article-title":"Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma","author":"Lezcano","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/DAD.0000000000001607","article-title":"Differential expression of cancer testis antigens on lentigo maligna and lentigo maligna melanoma","author":"Tio","year":"2020","journal-title":"Am. J. Derm."},{"key":"10.1016\/j.prp.2023.154915_bib5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/cup.13818","article-title":"PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features","author":"Raghavan","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib6","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/cup.13958","article-title":"The utility of PRAME staining in identifying malignant transformation of melanocytic nevi","author":"Lohman","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib7","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/his.14312","article-title":"PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna","author":"Gradecki","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2023.154915_bib8","first-page":"479","article-title":"PRAME expression in 155 cases of metastatic melanoma","author":"Gradecki","year":"2020","journal-title":"J. Cutan. Pathol."},{"issue":"15","key":"10.1016\/j.prp.2023.154915_bib9","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.3390\/cancers13153864","article-title":"Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas","volume":"13","author":"Gassenmaier","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154915_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.humpath.2021.12.008","article-title":"Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation","author":"Fattori","year":"2022","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/cup.14000","article-title":"The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors","author":"Alomari","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib12","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/DAD.0000000000001885","article-title":"Preferentially expressed antigen in melanoma immunostaining in a series of melanocytic neoplasms","author":"Googe","year":"2021","journal-title":"Am. J. Derm."},{"key":"10.1016\/j.prp.2023.154915_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2021.11.002","article-title":"Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi","author":"Hu","year":"2022","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.path.2021.01.001","article-title":"PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions","author":"Lezcano","year":"2021","journal-title":"Surg. Pathol. Clin."},{"key":"10.1016\/j.prp.2023.154915_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/his.14452","article-title":"PRAME expression in melanocytic lesions of the conjunctiva","author":"\u0160ekoranja","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2023.154915_bib16","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/cup.14212","article-title":"Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions","author":"Olds","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/cup.14130","article-title":"Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms","author":"McBride","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/DAD.0000000000002128","article-title":"PRAME expression in challenging dermal melanocytic neoplasms and soft tissue tumors with melanocytic differentiation","author":"Kline","year":"2022","journal-title":"Am. J. Derm."},{"key":"10.1016\/j.prp.2023.154915_bib19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/DAD.0000000000001951","article-title":"Correlation of FISH and PRAME immunohistochemistry in ambiguous superficial cutaneous melanocytic proliferations","author":"Harvey","year":"2021","journal-title":"Am. J. Derm."},{"key":"10.1016\/j.prp.2023.154915_bib20","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/cup.14078","article-title":"PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis","author":"LeBlanc","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2023.154915_bib22","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1046\/j.1365-2141.1998.00982.x","article-title":"PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells","author":"van Baren","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"13","key":"10.1016\/j.prp.2023.154915_bib23","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1158\/1078-0432.CCR-03-0813","article-title":"The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome","author":"Oberthuer","year":"2004","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2023.154915_bib24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.gene.2016.09.016","article-title":"PRAME is critical for breast cancer growth and metastasis","author":"Sun","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.prp.2023.154915_bib25","first-page":"4090","article-title":"Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?","author":"Neumann","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.prp.2023.154915_bib26","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/modpathol.2013.244","article-title":"Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma","author":"Hemminger","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","article-title":"Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1","author":"Iura","year":"2017","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib28","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.prp.2023.154915_bib29","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41379-019-0335-4","article-title":"Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas","author":"Toyama","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2023.154915_bib30","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","author":"Field","year":"2016","journal-title":"Clin. Cancer Res."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823006167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823006167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T07:12:40Z","timestamp":1759734760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033823006167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":30,"alternative-id":["S0344033823006167"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2023.154915","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PRAME expression in 137 primary cutaneous melanomas and comparison with 38 related metastases","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2023.154915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154915"}}